Journal: Chemistry & Biodiversity

Article Title: CA IX Inhibition by a Sulfonamide Compound: A Therapeutic Approach Against Breast Cancer

doi: 10.1002/cbdv.202501618

Figure Lengend Snippet: Protein and gene expression levels of CA IX, Caspase‐3 (CAS‐3), Vimentin (VIM), and E‐Cadherin (E‐CAD) across groups. The data were presented as mean ± SD ( n = 10). * p < 0.05 and ** p < 0.01 represent significance for comparisons between tumor (T) and normal breast (N) tissues.

Article Snippet: Protein levels of CA IX (Catalog No: E‐EL‐M0227, Elabscience), Vimentin (Catalog No: E2669Mo, BT Lab), E‐Cadherin (Catalog No: E‐EL‐M0211), and Caspase‐3 (Catalog No: E‐EL‐M0238) were determined using ELISA kits, following the manufacturer's protocols.

Techniques: Gene Expression

Journal: Cancer Medicine

Article Title: Role of Ca 2+ ‐Dependent Epithelial‐Mesenchymal Transition in Malignant Progression of Colorectal Cancer: Special Focus on REG Iα/ EDNRB

doi: 10.1002/cam4.71754

Figure Lengend Snippet: REG Iα promotes cell migration, invasion, and EMT via EDNRB. (A) Cell migration was assessed by Transwell assay. (B) Matrigel‐coated Transwell assay assessed cell invasion. (C) Western blot analysis of EMT‐related markers, including the epithelial marker E‐Cadherin and mesenchymal markers N‐Cadherin and Vimentin. β‐actin was used as the loading control. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: CHOP (Abcam, ab317378), Cleaved‐Caspase 3 (Abcam, ab32042), Cleaved‐PARP (Cell Signaling Technology, 9541), E‐Cadherin (BOSTER, PB9561), N‐Cadherin (BOSTER, A01577‐3), and Vimentin (BOSTER, BM4029).

Techniques: Migration, Transwell Assay, Western Blot, Marker, Control

Journal: Cancer Medicine

Article Title: Role of Ca 2+ ‐Dependent Epithelial‐Mesenchymal Transition in Malignant Progression of Colorectal Cancer: Special Focus on REG Iα/ EDNRB

doi: 10.1002/cam4.71754

Figure Lengend Snippet: The REG Iα‐EDNRB axis promotes cell migration, invasion, and EMT via the Ca 2+ signaling pathway. (A) Transwell assay assessed cell migration. (B) Cell invasion was assessed by Matrigel‐coated Transwell assay. (C) EMT‐related protein levels (E‐Cadherin, N‐Cadherin, Vimentin) were detected by Western blot. β‐actin served as the loading control. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: CHOP (Abcam, ab317378), Cleaved‐Caspase 3 (Abcam, ab32042), Cleaved‐PARP (Cell Signaling Technology, 9541), E‐Cadherin (BOSTER, PB9561), N‐Cadherin (BOSTER, A01577‐3), and Vimentin (BOSTER, BM4029).

Techniques: Migration, Transwell Assay, Western Blot, Control

Journal: Cancer Medicine

Article Title: Role of Ca 2+ ‐Dependent Epithelial‐Mesenchymal Transition in Malignant Progression of Colorectal Cancer: Special Focus on REG Iα/ EDNRB

doi: 10.1002/cam4.71754

Figure Lengend Snippet: The REG Iα‐EDNRB‐Ca 2+ axis promotes tumor growth and EMT in vivo. (A) Representative images of the xenograft tumors and excised tumor tissues from the indicated groups. (B) Statistical analysis of the final tumor weights. (C) Tumor growth curves measuring tumor volume over time. (D) H&E staining showed pathological changes in tumor tissues. (E) TUNEL assay detected cell apoptosis in tumor tissues. (F) Cell proliferation in tumor tissues was shown by Ki67 IHC staining. (G) Expression of REG Iα (Immunofluorescence, upper row) and EDNRB (IHC, lower row) in tumor tissues. (H) Western blot analysis of REG Iα, EDNRB, and p‐CaMKII protein levels in tumor tissues. β‐actin was used as the loading control. (I) Western blot analysis of EMT‐related proteins (E‐Cadherin, N‐Cadherin, Vimentin) in tumor tissues. β‐actin was used as the loading control. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: CHOP (Abcam, ab317378), Cleaved‐Caspase 3 (Abcam, ab32042), Cleaved‐PARP (Cell Signaling Technology, 9541), E‐Cadherin (BOSTER, PB9561), N‐Cadherin (BOSTER, A01577‐3), and Vimentin (BOSTER, BM4029).

Techniques: In Vivo, Staining, TUNEL Assay, Immunohistochemistry, Expressing, Immunofluorescence, Western Blot, Control

Journal: Oncology Letters

Article Title: Colon cancers carrying BRAF V600E and β-catenin T41A activating mutations are resistant to numerous common anticancer drugs

doi: 10.3892/ol.2018.7856

Figure Lengend Snippet: Patient-derived colon cancer xenograft tumors (F1 and F5) exhibited the same positivity and expression levels of protein biomarkers as the parental human cancer (F0). Immunohistochemical staining demonstrated common expression of SMAD3, ERBB1, c-MET, CDX2, E-cadherin and β-catenin between the primary cancer (F0) and the engrafted tumors (F1 and F5). Scale bar=50 µm. F, generation; ERBB1, epidermal growth factor receptor; CDX2, caudal type homeobox 2.

Article Snippet: Following two rinses (5 min each) in PBS, the sections were incubated with a biotin-conjugated goat anti-rabbit immunoglobulin (Ig)G (1:200; cat. no. BA1003; Boster Biological Technology, Pleasanton, CA, USA) following all primary antibody incubations except those of E-cadherin, for which a goat anti-mouse IgG secondary antibody was used (1:200; cat. no. BA1001; Boster Biological Technology) at room temperature for 20 min and rinsed twice (5 min each) in PBS.

Techniques: Derivative Assay, Expressing, Immunohistochemical staining, Staining

Journal: Oncology Letters

Article Title: Colon cancers carrying BRAF V600E and β-catenin T41A activating mutations are resistant to numerous common anticancer drugs

doi: 10.3892/ol.2018.7856

Figure Lengend Snippet: BRAF V600E and β-catenin T41A double mutations were identified in one PDCCX line. The point mutations (A) BRAF V600E and (B) β-catenin T41A were identified in the primary cancer and PDCCX tumors (F1 and F5). (C) A summary of mutations identified in this specific colon cancer and its derived PDCCX line. PDCCX, patient-derived colon cancer xenograft; F, generation; CTNNB1, β-catenin; APC, adenomatous polyposis coli; CDH1, cadherin 1; Syn, synonymous mutation.

Article Snippet: Following two rinses (5 min each) in PBS, the sections were incubated with a biotin-conjugated goat anti-rabbit immunoglobulin (Ig)G (1:200; cat. no. BA1003; Boster Biological Technology, Pleasanton, CA, USA) following all primary antibody incubations except those of E-cadherin, for which a goat anti-mouse IgG secondary antibody was used (1:200; cat. no. BA1001; Boster Biological Technology) at room temperature for 20 min and rinsed twice (5 min each) in PBS.

Techniques: Derivative Assay, Mutagenesis